13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
40 檔
1.2%
According to the latest 13F quarterly dataset, Alphabet Inc. managed an equity portfolio of $99.1B at the end of Q4 2024, spanning 40 distinct U.S. exchange-listed positions.
During Q4 2024, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GTLB | Gitlab Inc-cl A | Stock-Tech | 19.98% | -1.39% | -37.58% | |
| 2 | FRSH | Freshworks Inc-cl A | Stock-Other | 15.26% | -3.07% | — | |
| 3 | ARM | Arm Holdings Plc-adr | Stock-Tech | 14.08% | -6.69% | — | |
| 4 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 10.53% | -7.41% | -2.89% | |
| 5 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 8.52% | — | — | |
| 6 | PL | Planet Labs Pbc | Stock-Industrials | 7.51% | -23.35% | — | |
| 7 | PATH | Uipath Inc - Class A | Stock-Tech | 5.21% | -1.86% | — | |
| 8 | DXCM | Dexcom Inc | Stock-Healthcare | 4.69% | — | — | |
| 9 | ✓ | Verve Therapeutics Inc | Stock-Other | 4.06% | — | — | |
| 10 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 3.05% | -1.66% | — | |
| 11 | PRME | Prime Medicine Inc | Stock-Other | 2.56% | -1.38% | — | |
| 12 | VERA | Vera Therapeutics Inc | Stock-Other | 0.59% | -0.23% | — | |
| 13 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.59% | -0.27% | — | |
| 14 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.46% | -0.18% | — | |
| 15 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.38% | -0.13% | — | |
| 16 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.38% | -0.36% | — | |
| 17 | SANA | Sana Biotechnology Inc | Stock-Other | 0.27% | -0.19% | — | |
| 18 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 19 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.22% | — | — | |
| 20 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 21 | DM* | Desktop Metal Inc-a | Stock-Other | 0.15% | — | — | |
| 22 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 23 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.11% | — | — | |
| 24 | WGS | Genedx Holdings CORP | Stock-Other | 0.10% | — | — | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.10% | -0.02% | — | |
| 26 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.08% | — | — | |
| 27 | GUTS | Fractyl Health Inc | Stock-Other | 0.08% | — | — | |
| 28 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.08% | -0.02% | EXIT | |
| 29 | EXK | Exact Sciences CORP | Stock-Materials | 0.08% | — | — | |
| 30 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.06% | — | — | |
| 31 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.05% | -0.05% | — | |
| 32 | BHILQ | Benson Hill Inc | Stock-Other | 0.05% | — | — | |
| 33 | HYPR | Hyperfine Inc | Stock-Other | 0.05% | -0.02% | — | |
| 34 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.04% | — | — | |
| 35 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.02% | — | — | |
| 36 | ALEC | Alector Inc | Stock-Other | 0.02% | — | — | |
| 37 | FULC | Fulcrum Therapeutics Inc | Stock-Other | — | — | — | |
| 38 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — | |
| 39 | NVTA1EUR | Invitae CORP | Stock-Other | — | — | — | |
| 40 | HLTHQ | Cue Health Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 40 disclosed positions in Q4 2024.
During Q4 2024, Alphabet Inc.'s top holdings by market value included GTLB (20.0%)、FRSH (15.3%)、ARM (14.1%). The largest single position, GTLB, represented 20.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GTLB, FRSH, ARM) accounted for 1.2% of total reported equity market value during Q4 2024.
In Q4 2024, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.